Takahashi H, Ogata H, Shimizu M, Hashimoto K, Masuhara K, Kashiwada K, Someya K
Department of Biopharmaceutics, Meiji College of Pharmacy, Tokyo, Japan.
Biopharm Drug Dispos. 1993 Jul;14(5):409-18. doi: 10.1002/bdd.2510140507.
The relative bioavailability of two 100-mg disopyramide formulations which showed almost an 8- to 10-fold difference in their dissolution rates at pH 1.2 and 6.8 was determined in eight healthy subjects using a randomized block design. Although no significant differences in relative bioavailability were observed between the two formulations when based on the total disopyramide concentration, an almost 30 per cent difference in the extent of bioavailability was observed when assessed in terms of the unbound (+/-)- and (-)-disopyramide concentration, due probably to stereoselective nonlinear plasma protein binding. This suggests that unbound enantiomer parameters would be more sensitive to differences in bioavailability between two disopyramide formulations. Therefore, the type of concentration used would be an important factor for precise evaluation of the relative bioavailability of racemic drugs.
在8名健康受试者中采用随机区组设计,测定了两种100毫克双异丙吡胺制剂的相对生物利用度。这两种制剂在pH值1.2和6.8条件下的溶出速率相差近8至10倍。尽管基于双异丙吡胺总浓度时,两种制剂的相对生物利用度未观察到显著差异,但根据游离(+/-)-和(-)-双异丙吡胺浓度评估时,生物利用度程度存在近30%的差异,这可能是由于立体选择性非线性血浆蛋白结合所致。这表明游离对映体参数对两种双异丙吡胺制剂生物利用度的差异更为敏感。因此,所使用的浓度类型对于准确评估外消旋药物的相对生物利用度将是一个重要因素。